| |
|
|
|
GTC Conference, Omni Parker House, Boston, MA
Nov 07-08, 2011
The agenda for 8th Anti-infectives Partnering and Deal-making Conference is not yet available.
| To view the 2010 agenda, please visit http://anti-infectives-conference.com/index.php/agenda-2/ Below are the sessions for the 2011 Agenda.
| | | | | | Sessions:
Recent Advances in Anti-Infectives Development - Part I - Anti-bacterial
Recent Advances in Anti-Infectives Development - Part II - Anti-viral and Anti-fungal
Immunotherapy Approach to Infectious Diseases
Investments and Partnerships in the Anti-Infectives Space
Novel Technologies in Anti-Infectives
Current Models of Deals in Infectious Diseases
Innovative Partnering & Licensing Strategies
Scientific & Regulatory Updates |
|
|
|
|
|
|
|
|
|
Organized by:
|
|
GTC Conference |
|
|
Invited Speakers:
|
|
Danielle Drayton
Vice President, Research
Arlington Medical Resources, LLC
Michael N. Dudley, Pharm.D., FCCP, FIDSA
Senior Vice President, Research & Development and Chief Scientific Officer
Mpex Pharmaceuticals
Roger Echols
Infectious Disease Drug Development Consulting
Cynthia D. Green - Placeholder for Pfizer Colleague
Director, Wordwide Business Development
Pfizer
Richard Hatchett
Chief Medical Office and Deputy Director
BARDA
Vincent Hernandez
Director, Medicinal Chemistry
Anacor Pharmaceuticals
Michael G. Kurilla, M.D., Ph.D.
Director, Office of BioDefense Research Affairs;
Associate Director, BioDefense Product Development
DMID, NIAID, NIH, DHHS
Joseph Larsen, Ph.D.
Chief, Broad Spectrum Antimicrobials (BSA) Program;
Division of CBRN Countermeasures
DHHS/ASPR/BARDA
Steven Luperchio , Ph.D.
Senior Manager, Corporate Development
Cubist Pharmaceuticals
William F. Mongan
Executive Director US Business Development
AstraZeneca
John H. Rex, M.D., FACP
Infection Clinical Vice President, Oncology and Infection Therapy Area
AstraZeneca
Helga Rübsamen-Schaeff, Ph.D.
Chief Executive Officer
AiCuris GmbH & Co. KG
Jim Rock, MS, MBA
Director
IASO Pharma
Neil Ryder
Executive Director, Infectious Diseases
Novartis Institutes for BioMedical Research
Joyce A. Sutcliffe, Ph.D.
Senior Vice President, Biology
Tetraphase Pharmaceuticals
Glenn S. Tillotson, Ph.D., FIDSA, FCCP
Senior Vice President, Medical Affairs
Optimer Pharmaceuticals
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
Sept. 07, 2011
|
|
|
|
|
|
|
|
Registration:
|
|
https://www.gtcbio.com/index.php?option=com_register&cn=8th%20Anti-Infectives%20Partnering%20and%20Deal-making&cid=41
|
|
|
|
|
|
|
|
|